← Back to Patent Explorer
US4232037A Expired / Lapsed US ⏱️ 0.0 years remaining

2,6-Dialkoxybenzamides, intermediates, pharamaceutical compositions and methods for treatment of psychotic disorders

Assignee: AstraZeneca AB
•
Filing: 1979-03-08
•
Granted: 1980-11-04
•
Expires: 1999-03-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A compound of the formula <IMAGE> I wherein R1 is an alkyl group with 1-3 carbon atoms, R2 and R3 are the same or different and each is hydrogen, chlorine or bromine; and pharmaceutically acceptable salts and optical isomers thereof; methods and intermediates for the preparation of the compounds; pharmaceutical preparations containing them and their medical use for the treatment of psychoses.

Inventors

  • 👤 Gosta L. Florvall
  • 👤 Sven O. Ogren

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 21:44
CPC Classifications
C; C07; C07D; C07D207/00; C07D207/02; C07D207/04; C07D207/08; C07D207/09; A; A61; A61P; A61P25/00; A61P25/18; C07C; C07C51/00; C07C51/347; C07C51/363

Claims Analysis

Total Claims: 16
Claim 1
Independent Claim 44 words
A compound of the formula ##STR10## or a pharmaceutically acceptable salt thereof, in which formula R 1 represents an alkyl group with 1-3 carbon atoms, R 2 and R 3 are the same or different and each represents a hydrogen, chlorine or bromine atom.
Claim 2
Dependent Claim 44 words
A compound of the formula ##STR10## or a pharmaceutically acceptable salt thereof, in which formula R 1 represents an alkyl group with 1-3 carbon atoms, R 2 and R 3 are the same or different and each represents a hydrogen, chlorine or bromine atom.
Claim 3
Dependent Claim 54 words
A compound according to claim 1 with the formula I wherein R 1 is an alkyl group with 1-3 carbon atoms and R 2 and R 3 are the same or different and each represents a hydrogen, chlorine or bromine atom, provided that R 2 is chlorine or bromine when R 3 is hydrogen.
Claim 4
Dependent Claim 37 words
A compound according to claim 1 with the formula I wherein R 1 is a methyl group and R 2 and R 3 are the same or different and each represents a chlorine or a bromine atom.
Claim 5
Dependent Claim 19 words
A compound according to any of claims 1, 2 or 3 in the form of a substantially pure stereoisomer.
Claim 6
Dependent Claim 74 words
A pharmaceutical preparation which comprises as active ingredient at least one compound of the formula ##STR11## or a pharmaceutically acceptable salt thereof, in an amount effective to block the central dopamine receptors of the brain in which formula R 1 represents an alkyl group with 1-3 carbon atoms, R 2 and R 3 are the same or different and each represents a hydrogen, chlorine or bromine atom, in association with a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim 74 words
A pharmaceutical preparation which comprises as active ingredient at least one compound of the formula ##STR11## or a pharmaceutically acceptable salt thereof, in an amount effective to block the central dopamine receptors of the brain in which formula R 1 represents an alkyl group with 1-3 carbon atoms, R 2 and R 3 are the same or different and each represents a hydrogen, chlorine or bromine atom, in association with a pharmaceutically acceptable carrier.
Claim 8
Dependent Claim 34 words
A pharmaceutical preparation comprising as active ingredient an amount effective to block the dopamine receptors of the brain of a compound according to claims 2 or 3 in association with a pharmaceutically acceptable carrier.
Claim 9
Dependent Claim 44 words
A pharmaceutical preparation which comprises as an active ingredient an amount effective to block the dopamine receptors of the brain of a compound according to claims 2 or 3 in the form of a substantially pure stereoisomer in association with a pharmaceutically acceptable carrier.
Claim 10
Dependent Claim 11 words
A pharmaceutical preparation according to claim 5 in dosage unit form.
Claim 11
Dependent Claim 40 words
A pharmaceutical preparation which comprises as an active ingredient an amount effective to block the dopamine receptors of the brain of a compound according to claims 2 or 3 in association with a pharmaceutically acceptable carrier in dosage unit form.
Claim 12
Dependent Claim 48 words
A pharmaceutical preparation which comprises as an active ingredient an amount effective to block the dopamine receptors of the brain of a compound according to claims 2 or 3 in the form of a substantially pure stereoisomer in association with a pharmaceutically acceptable carrier in dosage unit form.
Claim 13
Independent Claim 70 words
A method for the treatment of psychoses in man, characterized by the administration to a host in need of such treatment of an effective amount of a compound of the formula ##STR12## or a pharmaceutically acceptable salt thereof, in which formula R 1 represents an alkyl group with 1-3 carbon atoms, R 2 and R 3 are the same or different and each represents a hydrogen, chlorine or bromine atom.
Claim 14
Independent Claim 70 words
A method for the treatment of psychoses in man, characterized by the administration to a host in need of such treatment of an effective amount of a compound of the formula ##STR12## or a pharmaceutically acceptable salt thereof, in which formula R 1 represents an alkyl group with 1-3 carbon atoms, R 2 and R 3 are the same or different and each represents a hydrogen, chlorine or bromine atom.
Claim 15
Dependent Claim 38 words
A method for the treatment of psychoses according to claim 11, characterized by the administration to a host in need of such treatment of an effective amount of a compound according to any of claims 2 or 3.
Claim 16
Independent Claim 51 words
A method for the treatment of psychoses in man characterized by the administration to a host in need of such treatment of an amount effective to block the dopamine receptors of the brain of a compound according to claims 1, 2 or 3 in the form of a substantially pure stereoisomer.

References Cited (Backward Citations)

DD67123A Cited
US3342826A Cited
BE695272A Cited
US3862139A Cited
DE2459221A1 Cited
US4029673A Cited
DE2556457A1 Cited
US4021567A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1983-11-04 1984-05-05 1984-11-04 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1987-11-04 1988-05-05 1988-11-04 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1991-11-04 1992-05-05 1992-11-04 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag